Recursion Pharmaceuticals (NASDAQ:RXRX) Director Blake Borgeson Sells 30,000 Shares of Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Blake Borgeson sold 30,000 shares of the company’s stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $3.34, for a total value of $100,200.00. Following the completion of the sale, the director owned 6,158,287 shares in the company, valued at $20,568,678.58. This trade represents a 0.48% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Blake Borgeson also recently made the following trade(s):

• On Tuesday, August 4th, Blake Borgeson sold 30,000 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $3.25, for a total transaction of $97,500.00.
• On Tuesday, July 7th, Blake Borgeson sold 40,000 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $3.96, for a total value of $158,400.00.

Recursion Pharmaceuticals Stock Performance

Recursion Pharmaceuticals stock opened at $3.38 on Thursday. Recursion Pharmaceuticals, Inc. has a 12-month low of $2.77 and a 12-month high of $7.18. The stock has a market capitalization of $1.81 billion, a price-to-earnings ratio of -3.25 and a beta of 1.07. The company has a quick ratio of 5.03, a current ratio of 5.03 and a debt-to-equity ratio of 0.01. The stock has a 50-day simple moving average of $3.33 and a 200 day simple moving average of $3.33.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its earnings results on Wednesday, August 5th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.01). Recursion Pharmaceuticals had a negative return on equity of 50.41% and a negative net margin of 945.94%.The company had revenue of $7.67 million for the quarter, compared to analyst estimates of $10.97 million. During the same quarter in the previous year, the company posted ($0.41) earnings per share. On average, research analysts anticipate that Recursion Pharmaceuticals, Inc. will post -0.92 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Several large investors have recently bought and sold shares of RXRX. International Assets Investment Management LLC bought a new position in Recursion Pharmaceuticals in the fourth quarter valued at approximately $31,000. Integral Investment Advisors Inc. bought a new stake in shares of Recursion Pharmaceuticals during the 1st quarter valued at $39,000. Sequoia Financial Advisors LLC bought a new stake in shares of Recursion Pharmaceuticals during the 4th quarter valued at $41,000. MQS Management LLC acquired a new position in shares of Recursion Pharmaceuticals in the 1st quarter valued at $41,000. Finally, Fund Advisors of America Inc FL acquired a new position in shares of Recursion Pharmaceuticals in the 2nd quarter valued at $45,000. 89.06% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts have commented on the company. Needham & Company LLC reiterated a “buy” rating and issued a $8.00 price objective on shares of Recursion Pharmaceuticals in a research report on Thursday, May 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research report on Friday, July 17th. Wall Street Zen raised Recursion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 29th. Finally, Morgan Stanley set a $5.30 price target on Recursion Pharmaceuticals in a report on Monday, August 17th. Two analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Recursion Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $8.06.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.